Buprenorphine: Not a silver bullet, and still controversial | Zendy

Sudheer Potru | Zendy; Michael Sprintz | Zendy; Antje M. Barreveld | Zendy; Lynn Kohan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Buprenorphine: Not a silver bullet, and still controversial

Author(s) -

Sudheer Potru,

Michael Sprintz,

Antje M. Barreveld,

Lynn Kohan

Publication year - 2021

Publication title -

journal of opioid management

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.331

H-Index - 39

eISSN - 2375-0146

pISSN - 1551-7489

DOI - 10.5055/jom.2021.0618

Subject(s) - buprenorphine , medicine , addiction medicine , addiction , pharmacy , substance abuse , psychiatry , alternative medicine , family medicine , medical emergency , opioid , receptor , pathology

We are practitioners of pain medicine and addiction medicine and also four of the seven members of the Multi-Society Ad Hoc Substance Use Disorder (SUD) Working Group comprised of representatives from anesthesia, pain, pharmacy, and addiction medicine societies. We are finalizing “tip sheets” and a consensus-based manuscript to provide guidance on the appropriate use and initiation of buprenorphine in the hospital setting by anesthesiologists, and in the outpatient setting by pain clinicians.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research